IDEAS home Printed from https://ideas.repec.org/a/scn/mngsci/y2018i2p44-51.html
   My bibliography  Save this article

Анализ проблем и возможностей использования референтного ценообразования органами государственной власти и местного самоуправления в сфере закупок и жилищного строительства // Analyzing the Problems and Opportunities of Reference Pricing for the Use by State Government and Local Self-Government Bodies in Procurement Activities and Housing Development

Author

Listed:
  • R. Rovbel L.

    (Development Department of Smolensk region, Smolensk)

  • Р. Ровбель Л.

    (Департамент инвестиционного развития Смоленской области, Смоленск)

Abstract

The problem of increasing transparency and elimination of corruption component in procurement is the most acute in the recent 10 years. The purpose of this study is to analyse the changes in the methods of calculating the initial (maximum) contract price (IMCP) through the introduction of reference prices and the analysis of the possibility of using reference pricing in the residential real estate market in the construction of social housing by the state. For reference pricing, prices for similar products are used for comparison. To achieve the given goal, there was carried an analysis of the legal act in the healthcare sector, which entered into force in October 2017 (Order of the Ministry of Health of the Russian Federation dated 26.10.2017 No. 871n “On approval of the procedure for determining the initial (maximum price) contract, the price of the contract concluded with a single supplier (contractor, performer), in the procurement of medicines for medical use”) and for the first time containing the concept of “reference price”, and also there were identified the main shortcomings of the existing unified state information system in the field of healthcare, which is proposed to be used as a basis for calculating reference prices and to other areas of procurement activities, in addition to healthcare. As a result of the conducted study, the methodology of reference pricing in the housing market was presented, and a proposal was made to attract evaluating companies and the institute of evaluation in general to carry out calculations on the economic value formation of different housing types for a particular segment of consumers. Transfer to the institute of evaluation of all issues, concerning reference pricing in the public housing construction market will enable to improve the level and quality of life of the population and to minimize the budget due to the increase in the price reliability level. Проблема повышения прозрачности и исключения коррупционной составляющей в закупочной деятельности является наиболее острой на протяжении последних 10 лет. Цель данного исследования — анализ изменения методов расчета начальной (максимальной) цены контракта (НМЦК) с помощью введения референтных цен и возможности применения референтного ценообразования на рынке жилой недвижимости при строительстве социального жилья государством. При референтном ценообразовании для сравнения используют цены на аналогичные товары. Для достижения поставленной цели проведен анализ нормативно-правового акта в сфере здравоохранения, вступившего в силу в октябре 2017 г. [приказ Минздрава России от 26.10.2017 № 871н «Об утверждении По- рядка определения начальной (максимальной цены) контракта, цены контракта, заключаемого с единственным поставщиком (подрядчиком, исполнителем), при осуществлении закупок лекарственных препаратов для медицинского применения»] и впервые содержащего понятие «референтная цена», а также были выявлены основные недостатки существующей единой государственной информационной системы в сфере здравоохранения, которая предлагается к использованию как база для расчета референтных цен и к другим областям закупочной деятельности, помимо здравоохранения. В результате проведенного исследования была представлена методика осуществления референтного ценообразования на рынке жилищного строительства и выдвинуто предложение о привлечении оценочных компаний и института оценки в целом для осуществления расчетов по формированию экономической ценности различных типов жилья для конкретного сегмента потребителей. Передача в институт оценки всех вопросов касательно референтного ценообразования на рынке государственного жилищного строительства будет способствовать повышению уровня, качества жизни населения и минимизации бюджетных средств в связи с повышением уровня достоверности цен.

Suggested Citation

  • R. Rovbel L. & Р. Ровбель Л., 2018. "Анализ проблем и возможностей использования референтного ценообразования органами государственной власти и местного самоуправления в сфере закупок и жилищного строительства // Analyzing the Problems a," Управленческие науки // Management Science, ФГОБУВО Финансовый университет при Правительстве Российской Федерации // Financial University under The Government of Russian Federation, vol. 8(2), pages 44-51.
  • Handle: RePEc:scn:mngsci:y:2018:i:2:p:44-51
    as

    Download full text from publisher

    File URL: https://managementscience.fa.ru/jour/article/viewFile/148/152.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
    2. Miraldo, Marisa, 2009. "Reference pricing and firms' pricing strategies," Journal of Health Economics, Elsevier, vol. 28(1), pages 176-197, January.
    3. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Timothy T. Brown & James C. Robinson, 2016. "Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 740-749, June.
    2. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    3. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    4. F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas, 2017. "Endogenous versus exogenous generic reference pricing for pharmaceuticals," International Journal of Health Economics and Management, Springer, vol. 17(4), pages 413-432, December.
    5. Ghislandi, Simone, 2011. "Competition and the Reference Pricing Scheme for pharmaceuticals," Journal of Health Economics, Elsevier, vol. 30(6), pages 1137-1149.
    6. Charitini Stavropoulou & Tommaso Valletti, 2015. "Compulsory licensing and access to drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 83-94, January.
    7. Paolo Buonanno & Matteo M. Galizzi, 2009. "Advocatus, et non latro? Testing the supplier-induced demand hypothesis for Italian courts of justice," Working Papers 0914, University of Brescia, Department of Economics.
    8. Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Health Economics, John Wiley & Sons, Ltd., vol. 20(6), pages 737-756, June.
    9. Ajay Bhaskarabhatla & Priyatam Anurag & Chirantan Chatterjee & Enrico Pennings, 2021. "How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry," Strategy Science, INFORMS, vol. 6(3), pages 209-227, September.
    10. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
    11. Jesus N. Sarol, Jr., 2014. "Effect of Government Mediated Access Pricing on Prices of Targeted Drugs in The Philippines," Journal of Asian Scientific Research, Asian Economic and Social Society, vol. 4(9), pages 473-489, September.
    12. Yasuhiro Hagiwara & Takeru Shiroiwa, 2022. "Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches," Medical Decision Making, , vol. 42(5), pages 672-683, July.
    13. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7), pages 624-638.
    14. Timothy Tyler Brown & Juan Pablo Atal, 2019. "How robust are reference pricing studies on outpatient medical procedures? Three different preprocessing techniques applied to difference‐in differences," Health Economics, John Wiley & Sons, Ltd., vol. 28(2), pages 280-298, February.
    15. Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas & Ullrich, Hannes, 2014. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," Journal of Health Economics, Elsevier, vol. 36(C), pages 174-187.
    16. Marion Aouad & Timothy T. Brown & Christopher M. Whaley, 2021. "Understanding the distributional impacts of health insurance reform: Evidence from a consumer cost‐sharing program," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2780-2793, November.
    17. Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
    18. Patrizio Armeni & Claudio Jommi & Monica Otto, 2016. "The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 963-977, November.
    19. Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    20. Margherita Neri;Adrian Towse;Martina Garau, 2018. "Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward," Briefing 002084, Office of Health Economics.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:scn:mngsci:y:2018:i:2:p:44-51. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Алексей Скалабан (email available below). General contact details of provider: http://managementscience.elpub.ru .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.